Arcline agrees Akron Bio sale to MaxCyte in $152m deal

Akron Bio supplies GMP-grade reagents and ancillary materials used in cell therapy manufacturing, including cytokines, growth factors, human plasma-derived products and media.

ByPEI Staff

2 minutes ago•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals North America US Healthcare Mid-market Briefs

Arcline agrees Akron Bio sale to MaxCyte in $152m deal

Arcline Investment Management